Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Randomized, double-blind, placebo-controlled, international trial of the oral iib/iiia antagonist lotrafiban in coronary and cerebrovascular disease

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Topol, Eric
  • Easton, D.
  • Harrington, R. A.
  • Amarenco, P.
  • Califf, R. M.
  • Graffagnino, C.
  • Davis, S.
  • Diener, H. C.
  • Ferguson, J.
  • Fitzgerald, D.
  • Granett, J.
  • Shuaib, A.
  • Koudstaal, P. J.
  • Theroux, P.
  • Van de Werf, F.
  • Sigmon, K.
  • Pieper, K.
  • Vallee, M.
  • Willerson, J. T.
  • Blockade Glycoprotein, IIb IIIa Rec

publication date

  • July 2003

journal

  • Circulation  Journal

subject areas

  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Aspirin
  • Benzodiazepines
  • Cerebrovascular Disorders
  • Coronary Disease
  • Creatinine
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Hemorrhage
  • Humans
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Piperidines
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Proportional Hazards Models
  • Risk Assessment
  • Treatment Outcome
scroll to property group menus

Research

keywords

  • antiplatelets
  • atherosclerosis
  • thrombosis
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0009-7322

Digital Object Identifier (DOI)

  • 10.1161/01.cir.0000084501.48570.f6

PubMed ID

  • 12874182
scroll to property group menus

Additional Document Info

start page

  • 399

end page

  • 406

volume

  • 108

issue

  • 4

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support